Eli Lilly makes Mounjaro for diabetes and Zepbound for weight loss, two brand names for the same medicine, tirzepatide. Together they brought in $16.1 billion of Lilly's $24.4 billion of revenue in the third quarter of 2026. In April 2026 it added Foundayo, a weight-loss pill.
Boxes with a corner arrow have their own map. Sizes show where a source gives one.
Outside forces
Things Eli Lilly can't control that affect its business. Tap one to see what to watch.
Weight-loss demandWorldwide sales volume rose 53% in the third quarter of 2026 while prices fell 15%. Lilly raised its 2026 revenue forecast to $91 billion to $92 billion.What to watch
Lower US pricesUS prices fell 7% in the quarter, mostly on Zepbound. The White House deal set lower prices for Medicare, Medicaid and the TrumpRx website.What to watch
Pill race with NovoNovo Nordisk launched a Wegovy pill in January 2026. Lilly's Foundayo followed in April and can be taken without food or water limits.What to watch
Yes. Both are tirzepatide. Mounjaro is approved for type 2 diabetes and Zepbound for weight loss.
What is Foundayo?
Lilly's weight-loss pill, orforglipron, approved by the FDA on April 1, 2026. It was discovered by Chugai and can be taken any time of day without food or water limits.
Who does Lilly sell its medicines to?
Mostly to drug wholesalers. Its three largest, McKesson, Cencora and Cardinal Health, were each 16% to 24% of 2025 revenue. It also sells directly to patients through LillyDirect.
Read every connection
All 8 connections as cards, with sources. It's the same detail you get by tapping a box on the map.Show allHide
Suppliers
The companies Eli Lilly relies on to make what it sells, with sources.
Chugai Pharmaceutical
Discovered its weight-loss pill
Size$184 million of Foundayo sales (Q3 2026)
Orforglipron, sold as Foundayo since April 2026, was discovered by Chugai, a Japanese drugmaker. Lilly develops and sells it.
What to watch: Foundayo sales, which reached $184 million in the third quarter of 2026, up from $98 million.
Lilly picked Amazon Pharmacy as one of the pharmacies that fills and ships prescriptions sent through LillyDirect, Lilly's own website for patients. Others include Walmart Pharmacy and Gifthealth.
What to watch: How much of Lilly's sales move to its own website.
Most of Lilly's medicines are sold to wholesalers that supply pharmacies and hospitals. In 2025 its three largest, McKesson, Cencora and Cardinal Health, were each 16% to 24% of revenue.
What to watch: Rebates and discounts, which lower what Lilly keeps from each sale.
Since November 6, 2026, patients on Hims & Hers can buy Zepbound and Foundayo directly at Lilly's self-pay prices, $299 and $149 a month to start. Lilly also works with Ro, WeightWatchers and GoodRx.
What to watch: Telehealth, which Lilly says is how 30% to 40% of patients get obesity medicines.
Lilly sells the diabetes drug Jardiance with Boehringer Ingelheim. It earned $410 million of sales milestones in the third quarter of 2026, and no more remain.
What to watch: A drop in this income now that the milestones are done.
Under a November 2025 deal with the White House, Medicare pays $245 a month for Zepbound and Mounjaro and covers them for obesity, with patients paying $50. State Medicaid programs can get the same price.
What to watch: How many seniors start treatment, and the lower price per patient.
Connections were last checked against company filings and news reports on Nov 21, 2026. Companies don't have to disclose every supplier or customer, so this map shows the most important ones that are publicly known, not every link.
How we check connections. StockTies is for information only. It is not investment advice. Spot something out of date? Tell us.